Loading...
Docoh

RAPT Therapeutics (RAPT)

News

From Benzinga Pro
Starbucks And 2 Other Stocks Insiders Are Buying
13 May 22
Long Ideas, News, Small Cap, Insider Trades, Markets, Trading Ideas
Although the Dow Jones jumped by more than 400 points on Friday, there were a few notable insider trades.
Piper Sandler Maintains Overweight on RAPT Therapeutics, Lowers Price Target to $30
12 May 22
News, Price Target, Analyst Ratings
Piper Sandler analyst Edward Tenthoff maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and lowers the price target from $52 to $30.
Recap: RAPT Therapeutics Q1 Earnings
11 May 22
Earnings, News
RAPT Therapeutics (NASDAQ:RAPT) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
RAPT Therapeutics Q1 EPS $(0.69) Down From $(0.66) YoY, Sales $641.00K Down From $1.22M YoY
11 May 22
Earnings, News
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.69) per share. This is a 4.55 percent decrease over losses of $(0.66) per share from the same period last year. The company reported $641.00 thousand in
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
4 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Wednesday's trading, 435 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
News, Options, Intraday Update, Markets
During Thursday, 849 stocks hit new 52-week lows.
RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis
28 Mar 22
News, Small Cap
RAPT Therapeutics, Inc. (NASDAQ: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmetRAPT Therapeutics, Inc.
RAPT Therapeutics Announces Biomarker Data From Phase 1b Clinical Trial Of RPT193 Consistent With Disease Modification In Atopic Dermatitis
28 Mar 22
News, FDA
RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet
RAPT Therapeutics's Return On Capital Employed Insights
14 Mar 22
Earnings
According to Benzinga Pro data, during Q4, RAPT Therapeutics (NASDAQ:RAPT) posted sales of $756.00 thousand. Earnings were up 3.87%, but RAPT Therapeutics still reported an overall loss of $17.93 million.
Piper Sandler Maintains Overweight on RAPT Therapeutics, Lowers Price Target to $52
11 Mar 22
News, Price Target, Analyst Ratings
Piper Sandler analyst Edward Tenthoff maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and lowers the price target from $61 to $52.
Wells Fargo Maintains Overweight on RAPT Therapeutics, Lowers Price Target to $55
11 Mar 22
News, Price Target, Analyst Ratings
Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and lowers the price target from $65 to $55.
RAPT Therapeutics: Q4 Earnings Insights
10 Mar 22
Earnings, News
RAPT Therapeutics (NASDAQ:RAPT) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
RAPT Therapeutics Q4 EPS $(0.61) Down From $(0.52) YoY, Sales $756.00K Down From $1.30M YoY
10 Mar 22
Earnings, News
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.61) per share. This is a 17.31 percent decrease over losses of $(0.52) per share from the same period last year. The company reported $756.00 thousand in